Heron Therapeutics
HRTX
100 hedge funds and large institutions have $1.07B invested in Heron Therapeutics in 2017 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 49 increasing their positions, 15 reducing their positions, and 16 closing their positions.
227% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 15
56% more capital invested
Capital invested by funds: $690M → $1.07B (+$385M)
50% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 16
1% more funds holding
Funds holding: 99 → 100 (+1)
0.64% less ownership
Funds ownership: 134.39% → 133.75% (-0.64%)
19% less call options, than puts
Call options by funds: $1.36M | Put options by funds: $1.68M
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$36.7M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$34M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$31.9M |
| 4 |
CC
Carlson Capital
Dallas,
Texas
|
+$30.5M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$29.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$10.4M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.73M |
| 3 |
VMI
VHCP Management II
New York
|
-$5.32M |
| 4 |
Millennium Management
New York
|
-$3.37M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$2.95M |
HRTX Hedge Fund Activity: Q1 2017 in Review
100 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2017, worth a combined $1.07B — up 56% from $690M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new HRTX positions and 16 closed out — a net gain of 8 holders — while 49 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $36.7M. The largest seller was Cormorant Asset Management, cutting an estimated $10.4M.
- 100 institutional investors held Heron Therapeutics (HRTX) as of Q1 2017, up from 99 in Q4 2016.
- Funds reported $1.07B of Heron Therapeutics stock for Q1 2017, up 56% quarter-over-quarter.
- 24 funds opened new Heron Therapeutics positions in Q1 2017 and 16 closed out, a net change of +8 holders.
- The largest Heron Therapeutics buyer in Q1 2017 was BlackRock, an estimated $36.7M added.
- The largest Heron Therapeutics seller in Q1 2017 was Cormorant Asset Management, an estimated $10.4M sold.
Based on aggregated 13F filings for Q1 2017.